Transpire Bio
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Multiple Therapeutics
Transpire Bio Inc. is an integrated US-based, revenue-generating, clinical-stage biopharmaceutical company headquartered in Sunrise, Florida. Transpire Bio harnesses its inhaled drug delivery expertise to improve patients’ lives by expanding access to important therapies and developing treatments for serious diseases where therapeutic options are significantly lacking. Transpire Bio has developed multiple proprietary inhalation technology platforms, including dry powder inhalers and soft-mist inhalers. Transpire Bio is building a pipeline of innovative inhalation medicines for Idiopathic Pulmonary Fibrosis (IPF), Pulmonary Arterial Hypertension (PAH), Diabetes, Obesity, Parkinson Disease Psychosis and Glioblastoma. For more information, please visit www.transpirebio.com.
Company HQ City:
Sunrise
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
2002
Lead Product in Development:
We have several products in development, all utilizing our proprietary inhalation technologies. Our own pipeline consists of several innovative, branded medicines: two products for Idiopathic Pulmonary Fibrosis, one product for obesity, one product for parkinson's psychosis and one oncology product. Additionally, we have 6 complex generic products in development for major asthma and COPD products currently on the market. Finally, we have signed a co-development partnership with a large pharmaceutical company and have already brought in tens of millions of dollars in upfront and milestone payments. The therapeutic category of this co-development product is publicly undisclosed at the moment
CEO
Dr. Xian-Ming Zeng
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
Five
When you expect your next catalyst update?
June 2027
What is your next catalyst (value inflection) update?
Additional ANDA files Accepted (two already accepted), progression of our innovative products through phase 1 and 2, along with the big pharma partner publicly disclosing us as their partner. Additionally, we hope to close another financing round with US investors and take the company public in the first half of 2027
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}